Symbol | Exchange | Currency |
|---|
Redx Pharma PLC (LON:REDX) announced it is moving to phase 2 of trials for its lead drug candidate RXC004, expected to start during the second half of 2021. The drug discovery and...
Redx Pharma PLC (LON:REDX) said it will receive the first ‘milestone payment’ under its early payments agreement with AstraZeneca (LON:AZN) following the pair’s licensing deal last...
Redx Pharma PLC (LON:REDX) said it will receive the first ‘milestone payment’ under its early payments agreement with AstraZeneca (LON:AZN) following the pair’s licensing deal last...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5,910.70 | 5,958.00 | 5,862.00 | +16.0 | +0.27% | 348.62K | London | |||
| 8,206.00 | 8,262.00 | 8,152.00 | +81.0 | +1.00% | 396.13K | London | |||
| 2,010.35 | 2,035.00 | 1,999.60 | -26.00 | -1.28% | 1.59M | London | |||
| 371.80 | 373.80 | 370.40 | -0.70 | -0.19% | 4.12M | London | |||
| 46.32 | 48.29 | 46.03 | -1.06 | -2.23% | 3.88M | London | |||
| 1,426.00 | 1,446.00 | 1,413.00 | -17.01 | -1.18% | 88.08K | London | |||
| 68.60 | 69.85 | 66.50 | +2.20 | +3.31% | 478.24K | London | |||
| 2,880.70 | 2,952.40 | 2,856.50 | -72.8 | -2.46% | 122.76K | London | |||
| 141.58 | 141.60 | 140.00 | +1.80 | +1.29% | 4.12M | London | |||
| 161.70 | 161.80 | 160.40 | +1.20 | +0.75% | 1.50M | London | |||
| 337.85 | 341.10 | 336.25 | -2.45 | -0.72% | 9.62M | London | |||
| 110.16 | 110.32 | 106.10 | +4.66 | +4.42% | 13.24M | London | |||
| 130.50 | 130.60 | 127.70 | +2.90 | +2.27% | 802.39K | London | |||
| 44.48 | 44.75 | 44.08 | +0.34 | +0.77% | 40.78M | London | |||
| 640.00 | 685.00 | 623.50 | -60.00 | -8.57% | 1.77M | London |
Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.